Department of Emergency Medicine, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.
Int J Mol Med. 2013 Nov;32(5):1215-21. doi: 10.3892/ijmm.2013.1494. Epub 2013 Sep 12.
Atherosclerotic plaque destabilization and rupture leads to acute coronary syndromes which cause serious damage to human health worldwide. However, there is currently a lack of efficient therapeutic methods. Mammalian target of rapamycin (mTOR) has been suggested to be involved in the development of atherosclerotic plaques and serves as a therapeutic target. The present study was performed to determine whether RNA interference (RNAi) of mTOR in vivo by LV‑mediated small hairpin RNA (shRNA) was capable of inhibiting the progression of atherosclerotic plaques. LV‑mediated shRNA against mTOR (LV‑shmTOR) was designed and obtained. Male apolipoprotein E‑deficient mice were fed a high‑fat diet and a constrictive collar was placed around the right carotid arteries of these mice to induce plaque formation. Eight weeks after surgery, mice were randomly divided into the mTOR RNA interference (LV‑shmTOR) group, receiving treatment with LV‑mTOR‑shRNA; the LV‑shCON group, receiving treatment with LV‑non‑specific‑shRNA; and the control group, receiving treatment with phosphate‑buffered saline. Following transfection, the mice were sacrificed to evaluate the effects of mTOR expression silencing on atherosclerosis. Transfection of LV‑mTOR‑shRNA markedly inhibited the mRNA and protein expression levels. Knockdown of mTOR ameliorated dysregulated blood lipid metabolism and stabilized aortic atherosclerotic plaques by decreasing the plaque area and increasing the fibrous cap and cap‑to‑core ratio. Furthermore, macrophages were decreased by silencing mTOR in atherosclerotic plaques. In addition, western blot analysis revealed that the knockdown of mTOR increased autophagy‑related protein 13 (Atg13) dephosphorylation and light chain 3‑I/light chain 3‑II (LC3‑I/LC3‑II) ratios, both of which were associated with a high activity of autophagy, suggesting an increase of autophagy in atherosclerotic plaques. Moreover, genes including matrix metalloproteinase 2, monocyte chemoattractant protein 1 and tissue factor, which promote plaque instability, were downregulated by silencing mTOR. These results demonstrate that LV‑mediated mTOR silencing by RNAi treatment induces macrophage autophagy and is a potential strategy for the treatment of atherosclerotic plaques.
动脉粥样硬化斑块的不稳定性和破裂导致急性冠脉综合征,给全世界人类健康造成严重损害。然而,目前缺乏有效的治疗方法。哺乳动物雷帕霉素靶蛋白(mTOR)已被证实参与了动脉粥样硬化斑块的形成,并可作为治疗靶点。本研究旨在探讨体内通过 LV 介导的小发夹 RNA(shRNA)对 mTOR 的 RNA 干扰(RNAi)是否能够抑制动脉粥样硬化斑块的进展。设计并获得了靶向 mTOR 的 LV 介导 shRNA(LV-shmTOR)。雄性载脂蛋白 E 缺陷小鼠给予高脂饮食喂养,并用缩窄环套于右侧颈动脉以诱导斑块形成。手术后 8 周,将小鼠随机分为 mTOR RNA 干扰(LV-shmTOR)组,给予 LV-mTOR-shRNA 治疗;LV-shCON 组,给予 LV-非特异性-shRNA 治疗;对照组,给予磷酸盐缓冲液治疗。转染后,处死小鼠以评估 mTOR 表达沉默对动脉粥样硬化的影响。LV-mTOR-shRNA 的转染显著抑制了 mTOR 的 mRNA 和蛋白表达水平。沉默 mTOR 可改善血脂代谢失调,并通过减少斑块面积和增加纤维帽及帽核比稳定主动脉粥样硬化斑块。此外,沉默 mTOR 可减少动脉粥样硬化斑块中的巨噬细胞。此外,Western blot 分析显示,沉默 mTOR 可增加自噬相关蛋白 13(Atg13)去磷酸化和 LC3-I/LC3-II(LC3-I/LC3-II)比值,这两者均与自噬活性增高有关,提示自噬在动脉粥样硬化斑块中增加。此外,沉默 mTOR 可下调基质金属蛋白酶 2、单核细胞趋化蛋白 1 和组织因子等促进斑块不稳定的基因。这些结果表明,LV 介导的 mTOR RNAi 治疗通过诱导巨噬细胞自噬而抑制动脉粥样硬化斑块的进展,可能是治疗动脉粥样硬化斑块的一种潜在策略。